Oxcarbazepine Tablet, Film Coated
Product Images NDC 70518-3197

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 70518-3197). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxcarbazepine 600mg 70518 3197 01

Oxcarbazepine 600 mg film-coated tablet label showing quantity of 100 tablets. Label indicates repackaging by RemedyRepack Inc. with original manufacturer Glenmark, Mahwah, NJ. Includes storage instructions and directions to see package insert, with NDC 70518-3197-01 and QR code present.*

FDA Label Image

Oxcarbazepine 600mg 70518 3197 02

Oxcarbazepine 600 mg film-coated tablet, quantity 1, repackaged by RemedyRepack Inc. The label includes storage instructions and manufacturer information for Glenmark, Mahwah, NJ. It is marked RX Only and includes a QR code and package insert directions.*

FDA Label Image

Remedy_label (Remedy Label)

Oxcarbazepine 600 mg film-coated tablets packaging label showing a quantity of 30 tablets. The label includes the proprietary name Oxcarbazepine, dosage strength of 600 mg, and indicates oral route in tablet form. Manufactured by Glenmark, Mahwah, NJ, and repackaged by RemedyRepack Inc., Indiana, PA. The label includes a note to keep medication out of reach of children and directs users to the package insert for directions.*

FDA Label Image

Figure1 (Figure1)

A Kaplan-Meier survival curve chart showing the effect of Oxcarbazepine versus placebo over time from Day 2 to Day 11. The solid line represents the Oxcarbazepine treatment group, and the dashed line represents the placebo group, with the y-axis indicating the event rate and a reported p-value of 0.0001 from a log-rank test.*

FDA Label Image

Figure2 (Figure2)

A Kaplan-Meier curve graph depicting the seizure rate over time in days from the first dose to the first seizure. It compares two groups: one treated with Oxcarbazepine and a placebo group. The seizure rate (y-axis) ranges from 0 to 1.0, and a log-rank test with a p-value of 0.046 is noted on the chart.*

FDA Label Image

Figure3 (Figure3)

A Kaplan-Meier survival curve chart comparing time to exit (days) between two groups labeled 'High' and 'Low'. The y-axis represents the exit rate from 0.0 to 1.0, and the x-axis shows time to exit in days, up to 130 days. A log-rank test p-value of 0.0001 is indicated, suggesting a statistically significant difference between the two groups.*

FDA Label Image

Figure4 (Figure4)

A Kaplan-Meier curve chart showing exit rates over time in days for two treatment groups labeled HIGH and LOW. The X-axis represents time to exit in days up to 130, and the Y-axis shows the exit rate from 0 to 1. The LOW group shows a faster and higher exit rate compared to the HIGH group, with a log-rank test p-value of 0.0001 indicated.*

FDA Label Image

Structure (Structure)

Chemical structure of Oxcarbazepine showing its molecular framework including the dibenzazepine ring system with ketone and amide functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.